Epidemiology, diagnosis, treatment and follow-up of cystic echinococcosis in asymptomatic carriers
| Autor: | Horacio Echenique, Marcos Seleiman, Mariano Sobrino, Jose Luis Labanchi, Juan Carlos Salvitti, Luis Sepulveda, Tamara Cornejo, Claudia Grizmado, Daniel Araya, Carlos Mercapide, Leonardo Uchiumi, Marcos Arezo, Guillermo Mujica, Mario Del Carpio, Eduardo Herrero, José Sustercic, Gabriel Talmon, Edmundo Larrieu, Hebe Tissot, José María Galvan, Oscar Panomarenko |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
Adult
Male medicine.medical_specialty Percutaneous Adolescent medicine.medical_treatment 030231 tropical medicine Argentina Albendazole Asymptomatic Young Adult 03 medical and health sciences 0302 clinical medicine Echinococcosis medicine Humans Cyst 030212 general & internal medicine Child Aged Aged 80 and over Anthelmintics business.industry Infant Newborn Public Health Environmental and Occupational Health Infant General Medicine Middle Aged medicine.disease Antiparasitic agent Surgery Infectious Diseases Child Preschool Asymptomatic Diseases Female Parasitology medicine.symptom business Asymptomatic carrier Watchful waiting Follow-Up Studies medicine.drug |
| Zdroj: | Transactions of The Royal Society of Tropical Medicine and Hygiene. 113:74-80 |
| ISSN: | 1878-3503 0035-9203 |
| DOI: | 10.1093/trstmh/try112 |
| Popis: | Background Rio Negro Province is endemic for cystic echinococcosis (CE). A CE control program includes early diagnosis in humans. During 1980-1996, screening was done with serology and surgery was the unique choice of treatment. Since 1997, ultrasound (US) has been the method of choice for screening, and new choices of treatment for asymptomatic carriers are discussed in the CE guidelines. Methods Between 1997 and 2016, 42 734 abdominal USs were performed, 192 new asymptomatic cases were diagnosed and underwent a protocol according to the size, location and type of cyst. Treatment options included active surveillance (US monitoring, 83 [43.3%]), antiparasitic (albendazole, 92 [47.9%]) and surgery (17 [8.8%], including percutaneous treatment). Results After 7.7 y of follow-up, of the cases under active surveillance, 28 (33.7%) had to change treatment: 5 (6%) to surgery and 22 (26.5%) to albendazole. Of the patients treated with albendazole, 3 (3.2%) were operated on and 13 (14%) were treated with a second cycle of albendazole. Conclusion As a result of the present study, resolution of CE in a non-surgical way with albendazole is confirmed to be effective in asymptomatic carriers with CE1 or CE3a cysts. An update eliminates the strategy of active surveillance in type CE1 cysts |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|